Pharmaceutical Stocks Fall As Trump’s Comments Rekindle Pricing Worries
Indian drug makers fell in early Thursday trades after U.S. President-elect Donald Trump said pharmaceutical companies were "getting away with murder" by charging high prices.
Trump also said he'd force the industry to bid for government business, in his first post-election press conference.
Pharma has a lot of lobbyists and a lot of power and there is very little bidding. We're the largest buyer of drugs in the world and yet we don't bid properly and we're going to save billions of dollars.Donald Trump, U.S. President-Elect
The fall in domestic drug makers was broadly in-line with the slump seen overnight in the U.S. healthcare stocks.
Trump threatens to force pharmaceutical industry to bid for government business. https://t.co/ondBDHtezm pic.twitter.com/FdDvkOfCvk
January 12, 2017Trump's threat to negotiate drug prices is applicable only to U.S. brand name companies, DG Shah, the secretary general of the Indian Pharmaceutical Alliance told BloombergQuint on the phone. The U.S. doesn't directly regulate medicine prices, unlike much of the rest of the globe.
This was only for innovative companies. He has said that he wants the ability to negotiate for state procurement. If he allows us (Indian pharma companies) to supply to Medicare, it will only open up the market for us.DG Shah, Secretary General, Indian Pharmaceutical AllianceAccording to Shah, Trump's comments were directed at American companies that manufacture in foreign locations and sell in the U.S. at higher prices.
My interpretation is that this comment does not apply to what we (Indian companies) sell in the U.S. During his campaign, he had repeatedly said that if it helps bringing medicine prices down, he has no issue with import of drugs. This is the interpretation of the statement he made, in the context he made.DG Shah, Secretary General, Indian Pharmaceutical Alliance“I am not saying Indian companies are not impacted,” added Shah, acknowledging the rub-off effect on Indian pharmaceutical companies that are focussed on the U.S. Leading pharmaceutical such as Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Sun Pharmaceutical Industries Ltd., Lupin Ltd., and Glenmark Pharmaceuticals Ltd., get between 35-50 percent of their revenues from the U.S.
Pricing Pressure
Pharmaceutical companies in the U.S. have been facing increasing pricing pressure in the U.S. for two years now, and larger companies have guided for low-to-mid single digits price erosion.
In 2016, the NSE Nifty Pharma Index clocked its worst yearly performance in eight years, falling 14.2 percent, after sharp increases in the costs of some life-saving drugs drew scrutiny in the press and among lawmakers.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.